2023-02-15

Camurus' Full Year Report 2022

Fluidcrystal Injection Depot 1

Camurus' Full Year Report for 2022 was published on February 14. 2022 was the first profitable year for Camurus, driven by strong sales growth.

"We ended the year with a fourth quarter with excellent performance across the organization, strong sales momentum, positive operating results, and continued pipeline progress. Camurus reported full year profitability for the first time while also investing half a billion SEK in our R&D pipeline", says Fredrik Tiberg, President & CEO.

Read the full report on Camurus' website: 

Camurus’ Full Year Report 2022 - Camurus

Latest news

2020-06-24

Positive results from Phase 2 study

Positive results from Phase 2 study of once-weekly FluidCrystal® formulation of setmelanotide in healthy volunteers…

Read more

2020-06-23

Camurus raises full year 2020 revenue guidance

The improvements are driven by increasing market shares of Buvidal® for treatment of opioid dependence in Europe and…

Read more

2020-05-07

Camurus Interim Report January-March 2020

”The number of patients treated with Buvidal® increased by 90 percent in the quarter”

Read more

2020-04-08

Camurus Annual Report for 2019

Camurus Annual Report for 2019 is now available at the company´s website.

Read more

2020-04-03

Camurus announces strong first quarter demand for Buvidal®

Camurus announced today continued strong revenue growth driven by increasing demand for weekly and monthly Buvidal®…

Read more